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Accepted 11 June 2014High-dose therapy (HDT) is effective in treating a variety
of hematologic conditions. However, despite signiﬁcant
reductions in treatment-related mortality over the past
several decades, subsequent development of therapy-related
myeloid neoplasm (t-MN) remains a signiﬁcant complica-
tion. A number of risk factors have been implicated in t-MN,
including prior therapy, age, poor mobilization for autolo-
gous stem cell transplantation (ASCT), and conditioning
regimen [1-5]. Incidence rates of t-MN have been reported as
high as 24.3% after ASCT [1], and the prognosis is exceedingly
poor [2,6,7]. Although most cases of t-MN harbor clonal
marrow cytogenetic abnormalities (CMCA) [6,7], the clinical
signiﬁcance of CMCA without morphologic or clinical fea-
tures of t-MN is less well established.
In this issue, Showel et al. report on 1 of the largest series
to date of CMCA after HDT, detailing the Johns Hopkins
experience with patients receiving ASCT or high-dose
cyclophosphamide [8]. Of 31 patients with CMCA in this se-
ries, 20 developed t-MN. The remaining 11 patients did not
meet criteria for t-MN over the duration of follow-up. Four of
these patients had only transient CMCA. At least another 4
patients had follow-up that was insufﬁcient to conﬁrm
persistence of the CMCA and/or to provide adequate time for
development of t-MN (given a delay of up to 3.2 years from
initial discovery of CMCA until overt t-MN in this cohort).
One patient did not develop t-MN, despite persistence of a
CMCA for 3 years and an additional 2.5 years of follow-up.
Notably, 2 patients, each with at least 5 years of follow-up
from ﬁrst discovery of CMCA, did not develop t-MN, in
spite of complex karyotypes in both cases and transient,
clinically signiﬁcant cytopenias in 1. The authors conclude
that CMCA alone are not sufﬁcient to establish a diagnosis of
t-MN and that correlation with morphology is also required.
At the very least, CMCA appears to be a risk factor for
subsequent t-MN, as 64.5% of patients with known CMCA ul-
timately developed t-MN in this series. This equates to a>18-
fold higher risk of t-MN in these patients than for the cohort as
awhole (whichhada 3.5% incidence of t-MN). Conversely, 95%DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.03.033.
Financial disclosure: See Acknowledgments on page 1077.
* Correspondence and reprint requests: Jonathan M. Gerber, MD, Levine
Cancer Institute, Carolinas HealthCare System, 1021 Morehead Medical
Drive, Suite 5300, Charlotte, NC 28204.
E-mail address: jonathan.gerber@carolinashealthcare.org
1083-8791/$ e see front matter  2014 American Society for Blood and
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2014.06.021of the patients with t-MN (who underwent cytogenetic
analysis) had CMCA. Even if the incidence of isolated CMCA
were underestimated (as suggested by the authors), it seems
likely that CMCA is still a signiﬁcant risk factor for t-MN.
The fact that some CMCA after HDT were transient and
did not progress to t-MN is not surprising. This phenomenon
can be explained by the fact that the CMCA may have arisen
in committed progenitor cells, which lacked the necessary
self-renewal potential to sustain a t-MN [9]. The persistence
of complex cytogenetic abnormalities for many years,
without progression to t-MN, is somewhat more unexpected.
Presumably, none of the CMCA in these cases were sufﬁcient
to transform the cells into a full-ﬂedged t-MN [10]. This is
substantiated by the fact that none of the patients with iso-
lated CMCA possessed persistent deletions of chromosome 5
or 7, either of whichmight have been adequate for malignant
transformation. Furthermore, although the t-MN cytogenetic
abnormalities were typically the dominant marrow clone,
the isolated CMCA constituted only a minority of the total
marrow cells in most cases, suggesting that these clones
lacked any growth advantage versus normal hematopoiesis.
Despite the size of the patient cohort, the small number of
CMCA in this series preclude many conclusions. However, it
is interesting that most cases of non-Hodgkin’s lymphoma
with CMCA progressed to t-MN, whereas aplastic anemia
patients represented a disproportionate share of the isolated
CMCA cases. These patient populations notably differed with
respect to previously reported risk factors of prior therapy
and type of HDT [2,5].
Given the grimprognosis and limited treatment options for
patients with t-MN, further work is needed to better identify
those patients at highest risk in order to prevent this dreaded
complication. At present, allogeneic blood or marrow trans-
plantation represents the only potentially curative option for t-
MN [11]. Although it may be premature to pursue this
aggressive treatment for all patients with isolated CMCA, the
high riskof t-MN in this populationmerits close follow-up. The
long latent phase in some patients offers time to conﬁrm the
diagnosis of t-MN and potentially still intervene early in the
course of the disease, but improved therapies are imperative.
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plantation, Alsina et al. and Donato et al. each report onwell-
sized prospective studies of allogeneic hematopoietic stem
cell transplantation (allo-HCT) with reduced intensity in
patients with multiple myeloma [1,2]. In the Alsina trial, the
use of lenalidomide maintenance therapy after allo-HCT is
evaluated for its contribution to additional disease control,
primarily as an immunomodulatory agent, and to allow time
for the graft-versus-myeloma effect to become established.
In the second study, a somewhat larger population of both
newly diagnosed patients and salvage patients demonstrates
that allo-HCT for myeloma can lead to sustained remission.
However, acute graft-versus-host disease (aGVHD) was sig-
niﬁcantly deleterious to overall survival and progression-free
survival in this trial, whereas chronic graft-versus-host dis-
ease (cGVHD)was favorable, suggesting an important role for
the graft-versus-myeloma effect.
In theﬁrst trial, a lowerdose of lenalidomide after allo-HCT
proved feasible, with lenalidomide initiated approximately
100 days after allo-HCT and at a 10 mg daily dose of lenali-
domide delivered 3 weeks out of 4. Although lenalidomide
after allo-HCTwas associated with a 38% incidence of aGVHD,
the survival outcomes observed were encouraging in thishigh-risk population and certainly warrant further study for
this approach, especially given theworse outcomes seenwith
other studies using higher doses and different schedules [3].
The second study also demonstrated encouraging overall
survival at 5 years of 59%; however, the 5-year overall survival
for patients who received transplantation as salvage was
substantially lower than in those who received it as consoli-
dation, after autologous transplantation during initial treat-
ment. Interestingly, univariate analysis conﬁrmed that in
patients receiving allogeneic transplantation as salvage,
advanced disease status before allogeneic stem cell trans-
plantation, increased number of prior autologous trans-
plantations, use of nonmyeloablative regimen, and presence
of aGVHD were adverse, versus response to allogeneic trans-
plantation and presence of cGVHD, with each of the latter
associated with a favorable impact on overall survival. The
positive effect of cGVHD was noteworthy; intriguingly, donor
type (be it unrelated or related), as well as cytogenetics and
age, were otherwise not signiﬁcant predictors of outcome.
Recognizing that the numbers in these studies remain rela-
tively small and selected, and thus these observations have to
be treated with some caution, the observations are nonethe-
less provocative, not least as they underscore the importance
of an effective immunologic platform in disease control to
achieve improved overall survival.
In aggregate, both studies also provide important infor-
mation to challenge a strongly held view in the ﬁeld of
myeloma that there is little or no role for allo-HCT [4,5]. Each
suggest a rationale for further prospective studies, and in
particular, they lend support to the further integration of
novel therapies into allo-HCT. Speciﬁcally, and as mentioned
above, other trials have shown that lenalidomide given at a
ﬁxed dose earlier in the allogeneic setting is associated with
unacceptable toxicity, in particular aGVHD [3]. The study by
Alsina et al. demonstrates that a 3-week on and 1-week off
schedule deployed later after transplantation, and similar to
that used in the postautologous setting, creates a major
